{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,13]],"date-time":"2026-05-13T11:32:11Z","timestamp":1778671931214,"version":"3.51.4"},"reference-count":45,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2021,2,1]],"date-time":"2021-02-01T00:00:00Z","timestamp":1612137600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,2,1]],"date-time":"2021-02-01T00:00:00Z","timestamp":1612137600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","internationaljournalofcardiology.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Journal of Cardiology"],"published-print":{"date-parts":[[2021,2]]},"DOI":"10.1016\/j.ijcard.2020.09.037","type":"journal-article","created":{"date-parts":[[2020,9,12]],"date-time":"2020-09-12T19:58:01Z","timestamp":1599940681000},"page":"78-83","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":11,"special_numbering":"C","title":["Direct oral anticoagulants in the prevention of stroke in breast cancer patients with atrial fibrillation during adjuvant endocrine therapy: A cohort study"],"prefix":"10.1016","volume":"324","author":[{"given":"Renata","family":"Pacholczak-Madej","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stanis\u0142awa","family":"Bazan-Socha","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lech","family":"Zar\u0119ba","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anetta","family":"Undas","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jerzy","family":"Dropi\u0144ski","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.ijcard.2020.09.037_bb0005","doi-asserted-by":"crossref","first-page":"3103","DOI":"10.1161\/STROKEAHA.113.002329","article-title":"Atrial fibrillation, stroke risk, and warfarin therapy revisited","volume":"44","author":"Bj\u00f6rck","year":"2013","journal-title":"Stroke."},{"key":"10.1016\/j.ijcard.2020.09.037_bb0010","first-page":"1","article-title":"Cancer increases the risk of atrial fibrillation during long-term follow-up (OPERA study)","volume":"13","author":"Huikuri","year":"2018","journal-title":"PLoS One"},{"key":"10.1016\/j.ijcard.2020.09.037_bb0015","doi-asserted-by":"crossref","first-page":"1090","DOI":"10.1016\/j.amjcard.2015.01.540","article-title":"Relation between cancer and atrial fibrillation (from the REasons for geographic and racial differences in stroke study)","volume":"115","author":"Neal","year":"2015","journal-title":"Am. J. Cardiol."},{"key":"10.1016\/j.ijcard.2020.09.037_bb0020","first-page":"47","article-title":"Bleeding in anticoagulated patients with atrial fibrillation : practical considerations","volume":"130","author":"Undas","year":"2020","journal-title":"Pol Arch Intern Med."},{"key":"10.1016\/j.ijcard.2020.09.037_bb0025","doi-asserted-by":"crossref","first-page":"1336","DOI":"10.1016\/j.jacc.2019.01.017","article-title":"Anticoagulation strategies in patients with Cancer","volume":"73","author":"Mosarla","year":"2019","journal-title":"J. Am. Coll. Cardiol."},{"key":"10.1016\/j.ijcard.2020.09.037_bb0030","unstructured":"Https:\/\/ecis.jrc.ec.europa., ECIS\u2014European Cancer Information System, (2020)."},{"key":"10.1016\/j.ijcard.2020.09.037_bb0035","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1007\/s11739-008-0124-4","article-title":"First diagnosis of colorectal or breast cancer and prevalence of atrial fibrillation","volume":"3","author":"Guzzetti","year":"2008","journal-title":"Intern. Emerg. Med."},{"key":"10.1016\/j.ijcard.2020.09.037_bb0040","series-title":"Trends and predictions to 2020 in breast cancer mortality in Europe","author":"Malvezzi","year":"2017"},{"key":"10.1016\/j.ijcard.2020.09.037_bb0045","doi-asserted-by":"crossref","first-page":"981","DOI":"10.1056\/NEJMoa1107039","article-title":"Apixaban versus warfarin in patients with atrial fibrillation","volume":"365","author":"Granger","year":"2011","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ijcard.2020.09.037_bb0050","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1056\/NEJMoa1009638","article-title":"Rivaroxaban versus warfarin in Nonvalvular atrial fibrillation","volume":"365","author":"Patel","year":"2011","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ijcard.2020.09.037_bb0055","doi-asserted-by":"crossref","first-page":"1139","DOI":"10.1056\/NEJMoa0905561","article-title":"Dabigatran versus warfarin in patients with atrial fibrillation","volume":"361","author":"Connolly","year":"2009","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ijcard.2020.09.037_bb0060","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1016\/j.breast.2019.05.017","article-title":"Current status of anticoagulation in patients with breast cancer and atrial fibrillation","volume":"46","author":"Pardo Sanz","year":"2019","journal-title":"Breast."},{"key":"10.1016\/j.ijcard.2020.09.037_bb0065","doi-asserted-by":"crossref","first-page":"1330","DOI":"10.1093\/eurheartj\/ehy136","article-title":"The 2018 European heart rhythm association practical guide on the use of non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation","volume":"39","author":"Steffel","year":"2018","journal-title":"Eur. Heart J."},{"key":"10.1016\/j.ijcard.2020.09.037_bb0070","first-page":"1440","article-title":"Eficacy and Safety of Edoxaban in Patients With Active Malignancy","volume":"130","author":"Fanola","year":"2017","journal-title":"Am J Med."},{"key":"10.1016\/j.ijcard.2020.09.037_bb0075","series-title":"Efficacy and Safety of Apixaban Versus Warfarin in Patients with Atrial Fibrillation and a History of Cancer","first-page":"1440","volume":"130","author":"Melloni","year":"2017"},{"key":"10.1016\/j.ijcard.2020.09.037_bb0080","doi-asserted-by":"crossref","first-page":"65","DOI":"10.15420\/ecr.2018.32.2","article-title":"AF in Cancer Patients: A Different Need for Anticoagulation?","volume":"14","author":"Sanz","year":"2019","journal-title":"Eur Cardiol."},{"key":"10.1016\/j.ijcard.2020.09.037_bb0085","doi-asserted-by":"crossref","first-page":"106567","DOI":"10.1016\/j.vph.2019.106567","article-title":"Extended treatment with non-vitamin K antagonist oral anticoagulants versus low-molecular-weight heparins in cancer patients following venous thromboembolism. A pilot study","volume":"120","author":"Stepien","year":"2019","journal-title":"Vascul. Pharmacol."},{"key":"10.1016\/j.ijcard.2020.09.037_bb0090","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/j.ejim.2018.10.012","article-title":"Atrial fibrillation in patients with active malignancy and use of anticoagulants: under-prescription but no adverse impact on all-cause mortality","volume":"59","author":"Malavasi","year":"2019","journal-title":"Eur. J. Intern. Med."},{"key":"10.1016\/j.ijcard.2020.09.037_bb0095","doi-asserted-by":"crossref","first-page":"2893","DOI":"10.1093\/eurheartj\/ehw210","article-title":"2016 ESC guidelines for the management of atrial fibrillation developed in collaboration with EACTS","volume":"37","author":"Kirchhof","year":"2016","journal-title":"Eur. Heart J."},{"key":"10.1016\/j.ijcard.2020.09.037_bb0100","doi-asserted-by":"crossref","first-page":"1165","DOI":"10.1002\/cam4.1054","article-title":"Thromboembolic and bleeding complications during oral anticoagulation therapy in cancer patients with atrial fibrillation: a Danish nationwide population-based cohort study","volume":"6","author":"Ording","year":"2017","journal-title":"Cancer Med."},{"key":"10.1016\/j.ijcard.2020.09.037_bb0105","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1182\/bloodadvances.2017010694","article-title":"Comparative effectiveness of direct oral anticoagulants and warfarin in patients with cancer and atrial fi brillation","volume":"13","author":"Shah","year":"2018","journal-title":"Blood Adv."},{"key":"10.1016\/j.ijcard.2020.09.037_bb0110","author":"Jassem","year":"2018","journal-title":"Breast Cancer"},{"key":"10.1016\/j.ijcard.2020.09.037_bb0115","first-page":"541","article-title":"Experience from a multicentre stroke register: a preliminary report","volume":"54","author":"Hatano","year":"1976","journal-title":"Bull. World Health Organ."},{"key":"10.1016\/j.ijcard.2020.09.037_bb0120","doi-asserted-by":"crossref","first-page":"2119","DOI":"10.1111\/jth.13140","article-title":"Definition of clinically relevant non-major bleeding in studies of anticoagulants in atrial fibrillation and venous thromboembolic disease in non-surgical patients: communication from the SSC of the ISTH","volume":"13","author":"Kaatz","year":"2015","journal-title":"J. Thromb. Haemost."},{"key":"10.1016\/j.ijcard.2020.09.037_bb0125","doi-asserted-by":"crossref","first-page":"955","DOI":"10.1016\/S0140-6736(13)62343-0","article-title":"Comparison of the efficacy and safety of new oral anticoagulants with warfarin in patients with atrial fibrillation: a meta-analysis of randomised trials","volume":"383","author":"Ruff","year":"2014","journal-title":"Lancet."},{"key":"10.1016\/j.ijcard.2020.09.037_bb0130","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1093\/ehjqcco\/qcy040","article-title":"Efficacy and safety of rivaroxaban vs. warfarin in patients with non-valvular atrial fibrillation and a history of cancer : observations from ROCKETAF","volume":"5","author":"Chen","year":"2019","journal-title":"Eur Hear. J Qual Care Clin Outcomes."},{"key":"10.1016\/j.ijcard.2020.09.037_bb0135","doi-asserted-by":"crossref","first-page":"515","DOI":"10.33963\/KP.14846","article-title":"Revisiting the risks of incident atrial fibrillation: A narrative review. Part 2","volume":"77","author":"Panchal","year":"2019","journal-title":"Kardiol. Pol."},{"key":"10.1016\/j.ijcard.2020.09.037_bb0140","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1161\/JAHA.116.004006","article-title":"Relation of body mass index with adverse outcomes among patients with atrial fibrillation: a meta-analysis and systematic review","volume":"5","author":"Zhu","year":"2016","journal-title":"J. Am. Heart Assoc."},{"key":"10.1016\/j.ijcard.2020.09.037_bb0145","doi-asserted-by":"crossref","first-page":"2222","DOI":"10.1016\/j.jacc.2014.09.028","article-title":"Aggressive risk factor reduction study for atrial fibrillation and implications for the outcome of ablation: the ARREST-AF cohort study","volume":"64","author":"Pathak","year":"2014","journal-title":"J. Am. Coll. Cardiol."},{"key":"10.1016\/j.ijcard.2020.09.037_bb0150","doi-asserted-by":"crossref","first-page":"1255","DOI":"10.1161\/CIRCULATIONAHA.107.744466","article-title":"Metabolic syndrome and risk of development of atrial fibrillation","volume":"117","author":"Watanabe","year":"2008","journal-title":"Circulation."},{"key":"10.1016\/j.ijcard.2020.09.037_bb0155","doi-asserted-by":"crossref","first-page":"682","DOI":"10.1016\/j.cgh.2016.10.011","article-title":"Major gastrointestinal bleeding often is caused by occult malignancy in patients receiving warfarin or Dabigatran to prevent stroke and systemic embolism from atrial fibrillation","volume":"15","author":"Flack","year":"2017","journal-title":"Clin. Gastroenterol. Hepatol."},{"key":"10.1016\/j.ijcard.2020.09.037_bb0160","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1002\/clc.22846","article-title":"Efficacy and safety of rivaroxaban compared with warfarin in patients with carotid artery disease and nonvalvular atrial fibrillation: insights from the ROCKET AF trial","volume":"41","author":"Kochar","year":"2018","journal-title":"Clin. Cardiol."},{"key":"10.1016\/j.ijcard.2020.09.037_bb0165","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1056\/NEJMoa1711948","article-title":"Edoxaban for the treatment of cancer-associated venous thromboembolism","volume":"378","author":"Raskob","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ijcard.2020.09.037_bb0175","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1371\/journal.pone.0102861","article-title":"Atrial fibrillation as a marker of occult cancer","volume":"9","author":"Ostenfeld","year":"2014","journal-title":"PLoS One"},{"key":"10.1016\/j.ijcard.2020.09.037_bb0180","first-page":"411","article-title":"Atrial function in patients with breast cancer after treatment with anthracyclines","volume":"107","author":"Yaylali","year":"2016","journal-title":"Arq. Bras. Cardiol."},{"key":"10.1016\/j.ijcard.2020.09.037_bb0185","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1016\/j.ijcard.2017.03.132","article-title":"Atrial fi brillation in cancer patients\u202f: hindsight, insight and foresight","volume":"240","author":"Mery","year":"2017","journal-title":"Int. J. Cardiol."},{"key":"10.1016\/j.ijcard.2020.09.037_bb0190","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1016\/j.blre.2019.03.005","article-title":"Atrial fibrillation and cancer \u2013 An unexplored field in cardiovascular oncology","volume":"35","author":"Chu","year":"2019","journal-title":"Blood Rev."},{"key":"10.1016\/j.ijcard.2020.09.037_bb0195","doi-asserted-by":"crossref","first-page":"1186","DOI":"10.33963\/KP.15042","article-title":"Non-Vitamin K antagonist oral anticoagulants in patients with atrial fibrillation and colorectal cancer: A single-center experience","volume":"77","author":"St\u0229pie\u0144","year":"2019","journal-title":"Kardiol. Pol."},{"key":"10.1016\/j.ijcard.2020.09.037_bb0200","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1016\/j.ijcard.2018.07.138","article-title":"Patients with cancer and atrial fibrillation treated with doacs: a prospective cohort study","volume":"269","author":"Vedovati","year":"2018","journal-title":"Int. J. Cardiol."},{"key":"10.1016\/j.ijcard.2020.09.037_bb0205","first-page":"539","article-title":"Occult cancer and thromboembolism: Current epidemiology and its practical implications","volume":"128","author":"Chao","year":"2018","journal-title":"Polish Arch. Intern. Med."},{"key":"10.1016\/j.ijcard.2020.09.037_bb0210","doi-asserted-by":"crossref","first-page":"1194","DOI":"10.1093\/annonc\/mdz173","article-title":"Early breast cancer: ESMO clinical practice guidelines for diagnosis, treatment and follow-up","volume":"30","author":"Cardoso","year":"2019","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.ijcard.2020.09.037_bb0215","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1002\/cncr.20347","article-title":"The risk of venous thromboembolic disease associated with adjuvant hormone therapy for breast carcinoma: a systematic review","volume":"101","author":"Deitcher","year":"2004","journal-title":"Cancer."},{"key":"10.1016\/j.ijcard.2020.09.037_bb0220","series-title":"Thrombosis and Hemostasis in Cancer","author":"Soff","year":"2019"},{"key":"10.1016\/j.ijcard.2020.09.037_bb0225","series-title":"Effect of tamoxifen on venous thrombosis risk factors in women without cancer : the Breast Cancer Prevention Trial","first-page":"109","author":"Cushman","year":"2003"},{"key":"10.1016\/j.ijcard.2020.09.037_bb0230","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1016\/j.thromres.2011.08.010","article-title":"Tamoxifen promotes superoxide production in platelets by activation of PI3-Kinase and NADPH oxidase pathways","volume":"129","author":"Shah","year":"2012","journal-title":"Thromb. Res."}],"container-title":["International Journal of Cardiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0167527320338183?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0167527320338183?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,28]],"date-time":"2025-09-28T20:50:02Z","timestamp":1759092602000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0167527320338183"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,2]]},"references-count":45,"alternative-id":["S0167527320338183"],"URL":"https:\/\/doi.org\/10.1016\/j.ijcard.2020.09.037","relation":{},"ISSN":["0167-5273"],"issn-type":[{"value":"0167-5273","type":"print"}],"subject":[],"published":{"date-parts":[[2021,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Direct oral anticoagulants in the prevention of stroke in breast cancer patients with atrial fibrillation during adjuvant endocrine therapy: A cohort study","name":"articletitle","label":"Article Title"},{"value":"International Journal of Cardiology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ijcard.2020.09.037","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}